Abstract

An estimand aims to clarify whether a clinical trial is actually measuring what we think/hope it is measuring.

While the ICH E9 revision focuses mainly on pre-approval activities and stakeholders, estimands will also play an important role in late phase.

Despite the current lack of clarity surrounding implementation, the HEOR community should welcome the revision.